• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Topical timolol reverses post-LASIK myopic regression

Article

Treatment with timolol maleate 0.5% can partially reverse myopic regression after LASIK for high myopia, said Joseph Frucht-Perry, MD, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Treatment with timolol maleate 0.5% can partially reverse myopic regression after LASIK for high myopia, said Joseph Frucht-Perry, MD, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

"Our experience in a series of 32 eyes showed twice daily use of the topical beta-blocker was associated with statistically significant reduction in myopia and improvement in uncorrected vision," Dr. Frucht-Perry said. "However, the effect on refraction is drug-dependent. While it was maintained with long-term treatment, the benefit terminated if timolol was discontinued, and there was less improvement in myopia following treatment renewal."

The 32 eyes on which he reported had a mean standard error (SE) prior to LASIK of –9.6 D (range –5.75 to –14.75 D) and a mean residual myopia of –1.87 D at 2 to 36 months postop. In all eyes, residual myopia was at least –1 D and was associated with decreased visual acuity.

Timolol was administered twice daily. After an average of about 1.8 months, mean SE improved to –0.94 D and mean UCVA had improved from 0.34 to 0.63. IOP did not change significantly.

Eleven patients stopped timolol after 5 to 20 months, and the discontinuation was associated with a regression of myopia to pretreatment levels. Mean SE among patients who restarted timolol was significantly lower than among patients who maintained ongoing treatment, –1.59 versus –1 D, respectively.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.